Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program
ConditionAneurysmal Subarachnoid Hemorrhage
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorXiaolin Chen, MD
About this trial
Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening cerebrovascular emergency with high mortality and disability rates. Despite advances in neuroimaging and interventional techniques, outcomes remain poor for many patients due to complex post-rupture complications such as delayed cerebral ischemia (DCI), pneumonia, and other systemic injuries. These secondary events critically affect neurological recovery, yet their molecular mechanisms are not fully understood.
This multicenter study aims to investigate the biological basis of post-rupture complications and prognosis in patients with aSAH through integrated multi-omics and clinical data analysis. Biospecimens including blood, cerebrospinal fluid, urine, and other relevant tissues will be collected for genomic, transcriptomic, proteomic, metabolomic, and imaging-omic profiling. By linking molecular data with clinical and imaging indicators, the study seeks to identify key pathways and biomarkers associated with secondary injury and outcome heterogeneity.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Adult patients aged ≥18 years;
Confirmed diagnosis of aneurysmal subarachnoid hemorrhage (aSAH) by CTA, or DSA;
Aneurysm secured by either microsurgical clipping or endovascular coiling during hospitalization;
Time from onset to aneurysm treatment ≤ 72 hours;
Disqualifiers
History of previous intracranial aneurysm surgery or embolization;
Non-aneurysmal SAH, traumatic SAH, or perimesencephalic non-aneurysmal hemorrhage;
Presence of malignancy, severe hepatic or renal dysfunction, or other systemic diseases that may affect survival or biomarker expression;
Severe cardiorespiratory insufficiency or unstable medical condition precluding study participation;
Trial population
Adult patients (≥18 years) with aneurysmal subarachnoid hemorrhage (aSAH) confirmed by CTA, or DSA, whose aneurysms are treated by microsurgical clipping or endovascular coiling within 72 hours after onset. Participants will be consecutively recruited from multiple tertiary neurosurgical centers.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Modified Rankin Scale (mRS) score for functional outcome
Functional outcome will be evaluated using the modified Rankin Scale (mRS), ranging from 0 (no symptoms) to 6 (death). Higher scores indicate greater disability. The distribution of mRS scores will be analyzed at predefined follow-up time points.
Time frame
3, 6, and 12 months after onsetSecondary outcomes
1
Incidence of rebleeding
Rebleeding is defined as sudden clinical deterioration during postoperative hospitalization, accompanied by evidence of increased bleeding on serial CT scans.
Time frame
After onset, up to 30 days2
Incidence of delayed cerebral ischemia (DCI)
DCI is defined as new focal neurological deficits or global neurological deterioration (a decrease of ≥2 points on the Glasgow Coma Scale) lasting more than 2 hours, after excluding intracranial hemorrhage, hydrocephalus, seizures, metabolic derangements, and infection, with or without radiological evidence of cerebral vasospasm.
Time frame
After onset, up to 30 days3
Incidence of anemia
Anemia is defined as hemoglobin (HGB) \< 120 g/L in adult males or \< 110 g/L in adult females.Severity is categorized as: mild (HGB 90-120 g/L), moderate (60-90 g/L), severe (30-60 g/L), and very severe (\<30 g/L).
Time frame
After onset, up to 30 days4
Incidence of pneumonia
Pneumonia is defined as the presence of clinical indications such as fever, cough, purulent sputum, or positive chest radiographic findings consistent with pulmonary infection.
Time frame
From enrollment to the end of follow-up at 3 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Xiaolin Chen, MD
Lead sponsor
Beijing Tiantan Hospital
Sponsor institution
Peking Union Medical College
Collaborator
Source ClinicalTrials.gov